JP2012502011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502011A5 JP2012502011A5 JP2011525575A JP2011525575A JP2012502011A5 JP 2012502011 A5 JP2012502011 A5 JP 2012502011A5 JP 2011525575 A JP2011525575 A JP 2011525575A JP 2011525575 A JP2011525575 A JP 2011525575A JP 2012502011 A5 JP2012502011 A5 JP 2012502011A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- growth hormone
- group
- binding protein
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 53
- 102000018997 Growth Hormone Human genes 0.000 claims description 17
- 108010051696 Growth Hormone Proteins 0.000 claims description 17
- 239000000122 growth hormone Substances 0.000 claims description 17
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 8
- 108010033419 somatotropin-binding protein Proteins 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- -1 phenylhydrazone Chemical class 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000007857 hydrazones Chemical class 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000007659 semicarbazones Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 150000002374 hemiaminals Chemical class 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 150000002466 imines Chemical class 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102000003601 transglutaminase Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 102000036124 hormone binding proteins Human genes 0.000 claims 1
- 108091011044 hormone binding proteins Proteins 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08163958 | 2008-09-09 | ||
| EP08163958.5 | 2008-09-09 | ||
| PCT/EP2009/061688 WO2010029107A1 (en) | 2008-09-09 | 2009-09-09 | Growth hormone conjugate with increased stability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502011A JP2012502011A (ja) | 2012-01-26 |
| JP2012502011A5 true JP2012502011A5 (enExample) | 2012-10-25 |
Family
ID=41210872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525575A Withdrawn JP2012502011A (ja) | 2008-09-09 | 2009-09-09 | 増加した安定性を有する成長ホルモンコンジュゲート |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110263501A1 (enExample) |
| EP (1) | EP2324056A1 (enExample) |
| JP (1) | JP2012502011A (enExample) |
| CN (1) | CN102149726A (enExample) |
| WO (1) | WO2010029107A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2525834T3 (pl) | 2010-01-22 | 2020-10-19 | Novo Nordisk Health Care Ag | Hormony wzrostu o przedłużonej skuteczności in-vivo |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| RU2639474C2 (ru) * | 2011-12-09 | 2017-12-21 | Метаболик Фармасьютикалс Пти Лтд | Применение фрагментов гормона роста |
| EP2981282B1 (en) | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Growth hormone compound formulation |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100508369B1 (ko) * | 2001-10-31 | 2005-08-17 | 주식회사 바이오폴리메드 | 펩타이드 스페이서를 갖는 생체적합성 고분자 |
| US7524813B2 (en) * | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| RU2385879C2 (ru) * | 2004-01-21 | 2010-04-10 | Ново Нордиск Хелс Кеа Аг | Способ конъюгации пептидов, опосредованной трансглутаминазой |
| US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| WO2006042848A2 (en) * | 2004-10-18 | 2006-04-27 | Novo Nordisk A/S | Growth hormone conjugates |
| TW200716179A (en) * | 2005-06-15 | 2007-05-01 | Novo Nordisk As | Transglutaminase mediated conjugation of growth hormone |
-
2009
- 2009-09-09 CN CN2009801350175A patent/CN102149726A/zh active Pending
- 2009-09-09 JP JP2011525575A patent/JP2012502011A/ja not_active Withdrawn
- 2009-09-09 US US13/058,985 patent/US20110263501A1/en not_active Abandoned
- 2009-09-09 EP EP09782814A patent/EP2324056A1/en not_active Withdrawn
- 2009-09-09 WO PCT/EP2009/061688 patent/WO2010029107A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502011A5 (enExample) | ||
| EP2842576B1 (en) | Transglutaminase mediated conjugation of peptides | |
| JP2020114818A5 (enExample) | ||
| US8299225B2 (en) | Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid | |
| JP2014518063A5 (enExample) | ||
| CN1638809A (zh) | 低分子量物质与修饰多糖的偶联 | |
| JP2018138588A (ja) | 新規リンカー、その製造方法およびその応用 | |
| CN104559213B (zh) | 一种聚三亚甲基碳酸酯与聚乙二醇改进聚肽膜亲水性与柔顺性的方法 | |
| CN1227500A (zh) | 药物复合物的制造方法 | |
| EA021001B1 (ru) | Биосинтетический пирролинкарбоксилизин и сайт-специфичные модификации белка за счет химической модификации остатков пирролинкарбоксилизина и пирролизина | |
| FR2645866A1 (fr) | Nouvelles lipopolyamines, leur preparation et leur emploi | |
| JP2013520986A5 (enExample) | ||
| AU2018329745A1 (en) | Antibody-mediated delivery of Cas9 to mammalian cells | |
| LU81881A1 (fr) | Procede de preparation d'un derive n-acyle selectivement protege d'un antibiotique aminoglycosidique | |
| CN104877982B (zh) | 制备肽/蛋白缀合物的方法和试剂 | |
| CN1646702A (zh) | 用于治疗性寡核苷酸的蛋白质载体系统 | |
| EP2593438B1 (fr) | Molecules porteuses de groupes associatifs | |
| JPWO2016047794A1 (ja) | 疎水性ペプチドの製造法 | |
| CN110054658A (zh) | 一种烟酰胺核糖的合成方法 | |
| CN1681535A (zh) | 羟烷基淀粉－变应原偶联物 | |
| JP7249591B2 (ja) | 分解性ポリエチレングリコール結合体 | |
| JP2010540488A5 (enExample) | ||
| JP6595600B2 (ja) | 糖タンパク質連鎖による部位特異的な複合体形成およびその方法 | |
| CN119731335A (zh) | 广谱病毒捕获纳米壳体 | |
| US9574236B2 (en) | Isolation of RNA-protein complexes using cross-linking reagents and oligonucleotides |